Navigation Links
Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Date:4/3/2008

SUNNYVALE, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced multiple presentations on its novel oncology and autoimmune disease drug candidates at the American Association for Cancer Research (AACR) 2008 Annual Meeting being held April 12-16, 2008, at the San Diego Convention Center in San Diego, CA.

Several presentations relate to the company's histone deacetylase(HDAC) inhibitor, which is now in a multicenter Phase 1 clinical trial, and the use of proprietary biomarkers to predict drug sensitivity. An additional presentation describes the activity of an HDAC-8 selective inhibitor that has demonstrated anti-inflammatory properties in preclinical studies.
The presentations are as follows:

Sunday, April 13, 2008:

-- Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors

Poster presentation: The histone deacetylase-8 selective inhibitor

PCI-34051 displays both anti-neoplastic and anti-inflammatory

activities by inducing apoptosis in T-cell derived tumors and blocking

IL-1B secretion in monocytes

Abstract #742: 8:00 a.m. - 12:00 p.m.

Presenter: Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.

-- Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors

Poster presentation: PCI-24781, a novel hydroxamic acid HDAC inhibitor,

raises intracellular levels of reactive oxygen species, induces

apoptosis and inhibits NFkB in leukemia models

Abstract #741: 8:00 a.m. - 12:00 p.m.

Presenter: Shan Gao, University of Texas MD Anderson Cancer Center

Monday, April 14, 2008:

-- Session: Histone Deacetylase and Heat Shock Protein Inhibitors

Oral presentation: Effects of histone deacetylase (HDAC) inhibitor

PCI-24781 on the development of gallbladder carcinoma in BK5.erbB2

mice

Abstract #2447: 11:10 - 11:25 a.m.

Presenter: Kaoru Kiguchi, M.D., Ph.D., The University of Texas MD

Anderson Cancer Center

-- Session: Novel Biological Therapy Agents

Poster presentation: Levels of tonic BCR signaling predict response to

the Btk inhibitor PCI-32765

Abstract #2396: 8:00 a.m. - 12:00 p.m.

Presenter: Joseph Buggy, Ph.D., Pharmacyclics, Inc.

Tuesday, April 15, 2008

-- Session: Molecular Predictors of Drug Sensitivity and Resistance

Oral presentation: Multiple mechanisms of apoptosis induction by the

histone deacetylase inhibitor PCI-24781 lead to predictive efficacy

biomarkers

Abstract #3613: 8:00 a.m. - 12:00 p.m.

Presenter: Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.

Wednesday, April 16, 2008

-- Session: Novel Small Molecule Cancer Therapeutics 1

Oral presentation: PCI-27483, a small molecule inhibitor of Factor

VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft

tumors

Abstract #5669: 8:00 a.m. - 12:00 p.m.

Presenter: Joseph Buggy, Ph.D., Pharmacyclics, Inc.

"Our strong presence at the AACR meeting highlights the breadth of our product portfolio in cancer and autoimmune diseases," said Richard A. Miller, M.D., president and chief executive officer of Pharmacyclics. "In addition to data on our HDAC inhibitor, other presentations describe our Factor VIIa and Btk inhibitors, which we anticipate will enter clinical testing later this year."

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months, our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; our future capital requirements; and the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2007 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
2. MiMedx Group Announces Post-split Name Change
3. Millennium Announces $200,000 Purchase Order From Greek Distributor
4. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
5. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
6. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
9. Human Pheromone Sciences Announces Quarterly and Full Year Results
10. Dragon Pharma announces 2007 full year financial results
11. Genaera Corporation Announces 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):